Physician profile
Daniel C Leung
NPI 1205003159
$2,434.76
in general payments reported to CMS, 2019-2025
21 companies · $679 in 2025
The $679 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $60.30 · 2022: $135 · 2023: $608 · 2024: $766 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985 · Education: $68.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.04 |
| Education | $68.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $446.20 | 2023-2025 | Entyvio |
| Lilly USA, LLC | $385.74 | 2024-2025 | Omvoh |
| Abbvie INC. | $350.78 | 2019-2025 | |
| Janssen Biotech, INC. | $277.53 | 2023-2025 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $192.65 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.44 | 2019-2022 | |
| Ardelyx, INC. | $122.77 | 2025 | Ibsrela |
| Qol Medical, LLC | $121.40 | 2023-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $114.54 | 2023-2024 | Yuflyma, Vegzelma, Zymfentra |
| Genzyme Corporation | $54.87 | 2023 | |
| Braintree Laboratories, INC. | $33.79 | 2022-2023 | Suflave |
| Regeneron Healthcare Solutions, INC. | $27.60 | 2025 | Dupixent |
| Stryker Corporation | $27.56 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Southern Anesthesia & Surgical, INC (Dba Ace Southern) | $23.54 | 2023 | Nuoss |
| Pacira Pharmaceuticals Incorporated | $23.43 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.39 | 2023 | Dificid |
| Heron Therapeutics, INC. | $20.99 | 2023 | Aponvie |
| Mallinckrodt Enterprises LLC | $17.51 | 2019 | |
| Acacia Pharma INC | $17.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.15 | 2025 | Iqirvo |
| Edwards Lifesciences Corporation | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Leung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.